Our Global Reach
What is thrombosis?
A blood clot which significantly slows or stops the passage of blood to and from the heart. In the arteries, it is a very common factor causing the majority of heart attacks and stroke; in the veins, it causes DVT and sudden post-operative death.
Who are we?
The Thrombosis Research Institute (TRI) has been at the centre of global understanding of thrombosis for 45 years. It is a member of UCLPartners, Academic Health Science Partnership, and is now based jointly in London and Bangalore.
What has the TRI achieved so far?
Development of the use of the blood thinning agent heparin which saves 300,000 lives worldwide each year; demonstration of how commonly fatal clots occur post-surgery and effectiveness of prophylactics; links to mortality in cancer patients.
What’s next?
Detecting thrombosis biomarkers – the naturally occurring molecules which will help us to pinpoint who is at risk of thrombosis, long before symptoms develop. Developing new therapies to prevent blood clots, heart attacks and stroke. Trials into a vaccine against heart disease, simple urine-based detector tests and more complex investigations into the root cause of CVD are under way.
